Vise Technologies Inc. Invests $208,000 in Enovis Corporation $ENOV

Vise Technologies Inc. bought a new position in Enovis Corporation (NYSE:ENOV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,646 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds have also made changes to their positions in the company. CWM LLC boosted its stake in Enovis by 564.9% in the 2nd quarter. CWM LLC now owns 3,790 shares of the company’s stock worth $119,000 after purchasing an additional 3,220 shares during the period. McIlrath & Eck LLC lifted its holdings in shares of Enovis by 52.2% in the first quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after purchasing an additional 1,808 shares in the last quarter. Humankind Investments LLC lifted its holdings in shares of Enovis by 8.6% in the first quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock valued at $217,000 after purchasing an additional 452 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the period. Finally, Quarry LP grew its holdings in shares of Enovis by 649.2% during the first quarter. Quarry LP now owns 6,720 shares of the company’s stock valued at $257,000 after buying an additional 5,823 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 0.0%

ENOV opened at $28.31 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The company has a market capitalization of $1.62 billion, a PE ratio of -1.99 and a beta of 1.67. The business has a 50-day moving average of $31.17 and a 200-day moving average of $31.21. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.75.

Enovis (NYSE:ENOV) last posted its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The company had revenue of $383.81 million during the quarter. Equities research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Transactions at Enovis

In other news, CEO Damien Mcdonald acquired 6,457 shares of Enovis stock in a transaction dated Thursday, September 11th. The stock was acquired at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the purchase, the chief executive officer owned 102,753 shares of the company’s stock, valued at $3,182,260.41. This represents a 6.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Bradley J. Tandy bought 3,200 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the purchase, the senior vice president directly owned 43,515 shares in the company, valued at $1,366,806.15. The trade was a 7.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. UBS Group dropped their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Wells Fargo & Company upped their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Needham & Company LLC reduced their price target on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Enovis currently has an average rating of “Moderate Buy” and a consensus target price of $51.17.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.